Christopher D. Carey
YOU?
Author Swipe
View article: Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Outcome (progression-free survival) - Cox multivariable models for beta2M
View article: Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Three distinct patterns of staining of HRS cell membranes were observed relative to the staining of reactive inflammatory cells: "positive" (Pos), "decreased" (Dec) and "negative" (Neg) for β2M, MHC class I and MHC class II. CHL #1: β2M an…
View article: Supplementary methods from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary methods from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Supplementary methods
View article: Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Outcome (progression-free survival) - Cox multivariable models for beta2M
View article: Data from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Data from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligand…
View article: Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Figure 1.Optimization IHC on pilot series of cHL cases. from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Three distinct patterns of staining of HRS cell membranes were observed relative to the staining of reactive inflammatory cells: "positive" (Pos), "decreased" (Dec) and "negative" (Neg) for β2M, MHC class I and MHC class II. CHL #1: β2M an…
View article: Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Percent exact agreement and weighted Cohen's kappa coefficient with bootstrap 95% confidence intervals.
View article: Supplementary methods from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary methods from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Supplementary methods
View article: Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Supplementary Table 1 from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
Percent exact agreement and weighted Cohen's kappa coefficient with bootstrap 95% confidence intervals.
View article: Data from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Data from Classical Hodgkin Lymphoma with Reduced β<sub>2</sub>M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status Open
In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligand…
View article: Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 1170K, Depletion of oncogenic drivers in NSCLC cell lines.
View article: Data from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Data from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung cancer (NSCLC) models.Experimental Design: The activity of ganetespib was co…
View article: Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 49K, Supplementary Immunohistochemical and Imaging Methods.
View article: Supplementary Table 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 294K, Ganetespib Biodistribution and Pharmacokinetic Parameters.
View article: Supplementary Figure 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 719K, Comparison of once-weekly and consecutive day dosing schedules among individual mice bearing NCI-H1975 xenografts.
View article: Supplementary Figure 6 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 6 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 776K, Effects of 17-AAG and ganetespib on cell viability and mutant ERBB2 expression in ERBB2-dependent Ba/F3 cells.
View article: Supplementary Figure 6 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 6 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 776K, Effects of 17-AAG and ganetespib on cell viability and mutant ERBB2 expression in ERBB2-dependent Ba/F3 cells.
View article: Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 1170K, Depletion of oncogenic drivers in NSCLC cell lines.
View article: Supplementary Figure 5 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 5 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 10283K, Induction of HSP70 and HSP27 expression following ganetespib exposure in NCI-H1975 xenografts after single and consecutive day treatment.
View article: Supplementary Table 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 136K, Median IC50's for NSCLC cell lines (with ganetespib and 17-AAG) with different genotypic subtypes.
View article: Supplementary Figure 5 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 5 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 10283K, Induction of HSP70 and HSP27 expression following ganetespib exposure in NCI-H1975 xenografts after single and consecutive day treatment.
View article: Supplementary Table 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 361K, Comparison of EGFR TKI and HSP90 inhibitor efficacy in Ba/F3 cells ectopically expressing different EGFR mutations.
View article: Supplementary Figure 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 365K, Activity of ganetespib in HCC827 xenografts.
View article: Supplementary Table 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 560K, Comparison of ganetespib and 17-AAG efficacy in NSCLC cell lines.
View article: Supplementary Figure 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 1349K, Depletion of receptor tyrosine kinases and suppression of downstream signaling in HCC827 cells in response to 17-AAG or ganetespib-mediated HSP90 inhibition.
View article: Supplementary Figure 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Figure 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 1349K, Depletion of receptor tyrosine kinases and suppression of downstream signaling in HCC827 cells in response to 17-AAG or ganetespib-mediated HSP90 inhibition.
View article: Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 49K, Supplementary Immunohistochemical and Imaging Methods.
View article: Supplementary Table 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 294K, Ganetespib Biodistribution and Pharmacokinetic Parameters.
View article: Supplementary Table 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Supplementary Table 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
PDF file, 361K, Comparison of EGFR TKI and HSP90 inhibitor efficacy in Ba/F3 cells ectopically expressing different EGFR mutations.
View article: Data from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer
Data from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Open
Purpose: We describe the anticancer activity of ganetespib, a novel non-geldanamycin heat shock protein 90 (HSP90) inhibitor, in non-small cell lung cancer (NSCLC) models.Experimental Design: The activity of ganetespib was co…